Background/aim: Clinical exacerbations characterized with neurological symptoms are observed in around 10% of Behçet's disease (BD) patients and may culminate in severe disability. Although certain immunological factors have been associated with disease activity in neuro-Behçet's disease (NBD), biomarkers for monitoring the clinical outcome of NBD have not been properly investigated. Materials and methods: Levels of neurofilament light chain (NFL), homeobox protein Hox-B3 (HoxB3), and YKL-40 were measured in cerebrospinal fluid (CSF) samples of 23 parenchymal (n = 16) and nonparenchymal (n = 7) NBD patients obtained during NBD attacks by ELISA. Parameters of clinical progression and outcome were assessed for an average follow-up period of 3.9 ± 1.3 years. Results: Parenchymal NBD patients showed elevated CSF levels of NFL, HoxB3, and YKL-40 as compared to nonparenchymal patients. NBD patients showing an increase in modified Rankin score (mRS) values during follow-up had significantly higher CSF NFL levels. Patients with relatively lower CSF NFL levels (
Background/Aim: Ovarian cancer, despite being the fifth most common gynecological malignancy, has the highest mortality rate. Recent clinical studies have explored the potential of natural products, like curcumin (CUR), to enhance conventional chemotherapy by targeting multiple cellular pathways. This study aimed to evaluate the effects of CUR and its analog, demethoxycurcumin (DMC), on human ovarian cancer and cisplatin-resistant ovarian cancer cell proliferation and apoptosis. Additionally, we investigated the expression of a candidate gene (GSTP-1), and microRNA (miR-133b) involvement in glutathione metabolism, a potential resistance mechanism in cisplatin-resistant ovarian cancer cells. Materials and Methods: Cell proliferation was measured using the WST-1 assay after exposing cisplatin-resistant (A2780cp) and sensitive (A2780) ovarian cancer cell lines to various concentrations of CUR and DMC for different time periods. Apoptosis was quantified using the Annexin V-FITC/PI assay. To understand the underlying mechanisms, we examined the expression levels of GSTP-1 and miR-133b using quantitative RT-PCR. Results: The WST-1 assay revealed that CUR and DMC inhibited cell proliferation in both cell lines, with cisplatin causing a sharper viability decline in A2780cp cells. Annexin V-PI staining detected early apoptosis induced by CUR, DMC, and their combinations in both cell lines at 12 hours, with no necrosis observed. Gene expression analysis showed a significant decrease in GSTP-1 and miR-133b levels in A2780cp cells compared to A2780 cells. The combination treatments, particularly Cur+DMC+Cisplatin, synergistically reduced GSTP-1 and miR-133b expression. Conclusion: This study demonstrated the potential of CUR and DMC to enhance the efficacy of cisplatin in ovarian cancer treatment. The observed decrease in GSTP-1 and miR-133b expression in cisplatin-resistant cells suggests their involvement in drug resistance and highlights their potential as therapeutic targets.
Granulomatous mastitis (GM) is a rare, benign, but chronic and recurrent inflammatory breast disease that significantly impacts physical and psychological well-being. It often presents symptoms such as pain, swelling, and discharge, leading to diagnostic confusion with malignancy. The etiology of GM remains unclear, though autoimmune and multifactorial components are suspected. This study aimed to explore the genetic underpinnings of GM using whole-exome sequencing (WES) on 22 GM patients and 52 healthy controls to identify single nucleotide variants (SNVs) and copy number variations (CNVs) potentially linked to the disease. WES analysis revealed novel SNVs in six genes: BRCA2 (rs169547), CFTR (rs4727853), NCF1 (rs10614), PTPN22 (rs2476601), HLA-DRB1 (seven variants), and C3 (rs406514). Notably, most of these variants are associated with immune regulation and inflammatory pathways, supporting the hypothesis that GM is an autoimmune disease. However, all identified variants were classified as benign according to the American College of Medical Genetics and Genomics (ACMG) guidelines, necessitating further investigation into their potential functional effects. Despite conducting CNV analysis, no significant variations were identified. This study represents a foundational step in linking genetic predisposition to GM and highlights the need for integrating genetic, clinical, and functional data to better understand GM’s pathophysiology. Future research should focus on larger cohorts, functional studies, and exploring multifactorial contributors to GM, including hormonal and environmental factors.
Chronic kidney disease (CKD) is an established risk factor for Parkinson’s disease (PD), but the molecular mechanisms linking these two conditions remain elusive. We performed a systems biology analysis by retrieving high-confidence gene–disease associations from DisGeNET v7.0 (PD: score ≥ 0.8, EI ≥ 0.4; CKD: score ≥ 0.6, EI ≥ 0.4) and constructing a protein–protein interaction (PPI) network via STRING v11.5 (confidence ≥ 0.700). Direct “molecular bridges” between CKD and PD proteins were identified and validated using independent databases. To corroborate biological feasibility, candidate proteins were cross-referenced with ExoCarta and Vesiclepedia databases for exosomal localization. Functional enrichment, tissue expression, and pathway analyses were conducted. Despite zero gene overlap (64 PD genes, 17 CKD genes), the PPI network showed significant convergence (81 nodes, 280 edges, PPI enrichment p < 1.0 × 10−16). Fifteen high-confidence molecular bridges were identified, including the Apolipoprotein A1 (APOA1)–α-synuclein (SNCA) interaction (combined score 0.883), which was independently validated by IntAct. Functional enrichment revealed specific association of APOA1–SNCA with “amyloid fiber formation” (false discovery rate (FDR) = 0.038). Both APOA1 and SNCA are annotated as exosome components (Kyoto Encyclopedia of Genes and Genomes (KEGG) ko04147) and were confirmed as consistent cargo in plasma, urine, and platelet-derived extracellular vesicles within proteomic databases (ExoCarta IDs: 335, 6622). Global pathway analysis highlighted inflammation, oxidative stress, and the advanced glycation end product (AGE)–receptor for AGE (RAGE) pathway. We propose an integrative model wherein CKD-induced dysregulation of APOA1 promotes α-synuclein misfolding and aggregation, and the co-packaging of these proteins into exosomes provides a plausible vehicle for kidney-to-brain propagation. This framework offers testable hypotheses and potential therapeutic targets for PD-CKD comorbidity.